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OBJECTIVES The present study was designed to assess the extent of myocardial injury in patients
undergoing transvenous implantation of an automatic implantable cardioverter-defibrillator
(ICD) using cardiac troponin I (cTNI), which is a highly specific marker of structural cardiac
injury.
BACKGROUND During ICD implantation, repetitive induction and termination of ventricular fibrillation
(VF) via endocardial direct current shocks is required to demonstrate the correct function of
the device. Transthoracic electrical shocks can cause myocardial cell injury.
METHODS Measurements of total creatine kinase (CK), CK-MB, myoglobin, cardiac troponin T
(cTNT) and cTNI were obtained before and after ICD implantation in 49 consecutive
patients. Blood samples were drawn before and 2, 4, 8, and 24 h after implantation.
RESULTS Elevations of CK, CK-MB, myoglobin, cTNT and cTNI above cut-off level were found in
25%, 6%, 76%, 37% and 14% of patients, respectively, with peak cTNI concentrations ranging
from 1.7 to 5.5 ng/ml. Cumulative defibrillation energy (DFE), mean DFE, cumulative VF
time, number of shocks as well as prior myocardial infarction (MI) were found to be
significantly related to a rise of cTNI. Mean DFE $ 18 J and a recent MI were identified as
strong risk factors for cTNI rise.
CONCLUSIONS During transvenous ICD implantation myocardial injury as assessed by cTNI rise occurs in
about 14% of the patients. Peak cTNI concentrations are only minimally elevated reflecting
subtle myocardial cell damage. Patients with a recent MI and a mean DFE $ 18 J seem to
be prone to cTNI rise. (J Am Coll Cardiol 1999;34:402–8) © 1999 by the American College
of Cardiology
During implantation of automatic implantable cardioverter-
defibrillators (ICDs), induction and termination of several
episodes of ventricular fibrillation (VF) are required to
demonstrate correct sensing and defibrillation properties of
the device. It is known from intraoperative transesophageal
echocardiographic studies that ventricular function may be
temporarily compromised during ICD testing (1–3). How-
ever, the extent of permanent myocardial cell damage due to
intraoperative testing is unclear. Also, it is not known which
kind of patients are particularly prone to suffer myocardial
cell injury during implantation, nor is it known what
number of ICD tests are required to cause myocardial cell
damage. Hence, assessment of the degree of myocardial cell
damage due to ICD testing was the purpose of this study.
Recently, sensitive and specific markers of structural
myocardial injury have been developed and introduced into
clinical practice that overcome the drawbacks of creatine
kinase (CK) and CK-MB measurements, that is, lack of
cardiac specificity and unfavorable time course (4–10).
Cardiac troponin I (cTNI) and cardiac troponin T (cTNT)
are new serum markers that are sensitive and highly specific
to detect myocardial cell injury (11–18). Both markers are
regulatory proteins associated with the actin/myosin fila-
ments of striated muscle and are released from the cell in the
presence of myocardial necrosis in close relation to the
degree and quantity of myocardial cell damage. With
progressively higher levels of these markers, the magnitude
of myocardial necrosis increases, providing further prognos-
tic importance (11,19–23).
However, unlike cTNT, cTNI is not expressed in skeletal
muscle during neonatal development. Therefore, cross-
reactivity of cTNI monoclonal antibodies with skeletal
muscle forms is not likely to occur and has not yet been
reported (24–27). Accordingly, elevations of cTNI do not
From the Department of Cardiology and *Department of Clinical Chemistry,
University of Giessen, Giessen, Germany.
Manuscript received June 22, 1998; revised manuscript received March 6, 1999,
accepted April 9, 1999.
Journal of the American College of Cardiology Vol. 34, No. 2, 1999
© 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00
Published by Elsevier Science Inc. PII S0735-1097(99)00194-1
occur in serum of healthy subjects or even in patients with
skeletal muscle disease or renal failure unless acute myocar-
dial injury is present (28–30). Given these features of cTNT
and cTNI as markers of myocardial necrosis, the present
study was designed to assess the extent of myocardial cell
damage in patients undergoing transvenous implantation of
an automatic ICD using the previously mentioned conven-
tional and new serum markers.
PATIENTS AND METHODS
Patients. A total of 49 consecutive patients undergoing
transvenous implantation of an ICD were enrolled in the
study. All patients gave written informed consent to the
procedure. Patient characteristics are detailed in Table 1.
Thirty of 37 patients suffering from coronary artery disease
(CAD) had a history of myocardial infarction (MI); 6 of
these MIs had occurred within the last six months before
implantation. Revascularization procedures such as angio-
plasty, coronary artery stenting or bypass grafting had been
completed in all CAD patients before ICD implantation.
None of these patients had stable or unstable angina.
Twelve of 49 patients had normal coronary arteries, that is,
8 patients with dilated cardiomyopathy, 2 patients with
idiopathic ventricular fibrillation (VF), 1 patient with val-
vular heart disease and 1 patient with right ventricular
dysplasia. Twelve of 49 patients had impaired renal func-
tion, with serum creatinine ranging from 1.4 to 8.9 mg/dl.
In all patients, left ventricular mass was estimated by
echocardiography using the penn-cube formula (31). Mean
left ventricular mass was 319.7 6 117.6 g. Left ventricular
ejection fraction (LVEF) measured either by angiography or
echocardiography was 33.8 6 16.4%.
Indication of ICD implantation was 1) documented,
unstable, sustained ventricular tachycardia (VT) in 17 pa-
tients or documented VF in 16 patients; 2) spontaneous
nonsustained VT with inducible, sustained, unstable VT
during electrophysiologic study in 15 patients; and 3) severe
syncope in the post-MI phase in one patient. None of the
patients showed evidence of acute MI perioperatively as
assessed by serum markers and routine electrocardiogram or
had ICD discharges within the first 24 h after implantation.
Implantation procedure. The ICDs used were a Jewel
Model 7219 in 4 of 49 patients, Model 7220 in 17 of 49
patients, Model 7221 in 10 of 49 patients, Model 7223 in
14 of 49 patients, and a GEM DR 7271 (Medtronic,
Minneapolis, Minnesota) in 4 of 49 patients, respectively.
Leads used were tined, steroid-eluting electrodes in 33 of 49
patients (67%) and screw-in electrodes in 16 of 49 patients
(33%). The lowest energy required to terminate VF was
defined “defibrillation threshold” (DFT). The DFT testing
was performed using a binary search algorithm starting at an
energy of 12 joules (J) (32). Implantation criteria were met
if the DFT was #22 J, or, if the DFT was .22 J, if two
subsequently induced VF episodes could be defibrillated
successfully with #24 J. If the patient failed to meet
implantation criteria, repositioning of the ventricular elec-
trode was performed before retesting. An additional lead
system (e.g., superior vena cava lead or subcutaneous patch
electrode) was required in four patients to fulfill implanta-
tion criteria. Reversed polarity was tested in 36 of 49
patients after assessment of the initial DFT. If VF proved to
be converted successfully at a lower energy level using
reversed polarity, further DFT testing with reversed polarity
was performed.
Evaluation of serum markers. Blood specimens were ob-
tained preoperatively in all patients and included measure-
ments of total CK activity, CK-MB activity, myoglobin,
cTNT and cTNI, respectively. The measurements were
repeated 2, 4, 8 and 24 h after surgery in all patients.
Venous blood samples were drawn into tubes and centri-
fuged at 4000g for 5 min. Serum was stored at 224°C up to
72 h, thawed once and assayed in batches. Assays and
measurements were performed and interpreted by individ-
uals blinded to the clinical data.
Total CK activity (upper reference limit 80 U/l) was
measured on a BM/Hitachi 717 automatic analyzer using a
kinetic-enzymatic assay (CK NAC-activated, Boehringer
Mannheim, Germany) according to an “optimized standard
method” (33). The CK-MB activity (upper reference limit
10 U/l) was determined using a commercially available
Abbreviations and Acronyms
CAD 5 coronary artery disease
CK 5 creatine kinase
cTNI 5 cardiac troponin I
cTNT 5 cardiac troponin T
DFE 5 defibrillation energy
DFT 5 defibrillation threshold
ICD 5 implantable cardioverter-defibrillator
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
VT/VF 5 ventricular tachycardia/ventricular fibrillation
Table 1. Patient Characteristics
All Patients
(n 5 49)
Age (yrs) 62.2 6 9.9
Sex (male/female) 41/8
LV ejection fraction (%) 33.8 6 16.4
LV mass (g) 319.7 6 117.6
Cardiovascular disease
CAD 37
Prior MI 30
Dilated CMP 8
Others 4
Data are presented as mean 6 SD or number of patients.
CAD 5 coronary artery disease; CMP 5 cardiomyopathy; LV 5 left ventricular;
MI 5 myocardial infarction.
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immuno-inhibition assay (CK-MB NAC-activated, Boehr-
inger Mannheim, Germany).
Myoglobin was measured using a commercially available
immunonephelometric assay (N Latex Myoglobin Reagent,
Behringwerke Marburg, Germany) with the upper reference
limit of 70 mg/l and the lower limit of detection of 25 mg/l.
Cardiac troponin I was measured by the Stratus II
fluorometric enzyme immunoassay (Dade International,
Miami, Florida), which utilizes two monoclonal antibodies
specific for two different epitopes on the cTNI molecule. No
cross-reactivity has been observed with cTNI found in
human skeletal muscle (29). In healthy subjects without
evidence of cardiac disease, cTNI concentration was less
than the minimum detectable concentration of the assay,
which is 0.35 ng/ml. Studies performed with this assay on
samples of hospitalized patients due to chest pain have
defined the upper reference limit for patients without MI to
be 1.5 ng/ml based on a 95% cutoff value by nonparametric
analysis (34–36). Therefore, the diagnostic cutoff value was
defined to be 1.5 ng/ml in our study.
Cardiac troponin T was measured by an enzyme-linked
immunosorbent assay with an ES 600 analyzer using
streptavidin-coated tubes (Boehringer Mannheim, Germa-
ny). The capture antibody is specific for cTNT, whereas the
detection antibody shows a 12% rate of cross-reactivity with
skeletal muscle troponin T (16). Troponin T levels above
the normal range may be found in samples of patients with
chronic renal failure and patients on dialysis (28). The lower
limit of detection of the assay as stated by the manufacturer
is 0.02 ng/ml; the diagnostic cutoff for cTNT is 0.1 ng/ml.
Statistical analysis. Analyses were performed using a com-
mercially distributed software package (Statview, version 4.5,
Cherwell Scientific Publishing, Oxford, United Kingdom, and
PCS, version 2.1, Topsoft, Hannover, Germany) including
paired and unpaired nonparametric tests. Comparison of de-
mographical data was performed with a Mann-Whitney U test
for continuous variables and a chi-square test (or Fisher exact
test if numbers were small) for categorical variables. To test for
the difference in serum markers at baseline and after ICD
implantation a Wilcoxon signed rank sum test was used.
Relationships between variables were examined using univari-
ate (Fisher exact test) and multivariate analysis (logistic regres-
sion model for dichotomous variables). Variables entered into
the multivariate model were those that gave statistically signif-
icant results in the univariate analysis. In addition, LVEF
#30% and mean defibrillation energy (DFE) $18 J were used
in the multivariate analysis since these variables represent
widely used and clinically important parameters. All data are
expressed as mean 6 SD. A p-value ,0.05 was considered
statistically significant.
RESULTS
Evaluation of all serum markers. In total, a significant rise
from mean baseline values measured preoperatively to mean
peak values measured postoperatively was observed in all
serum markers. However, the ratio of CK-MB to total CK
showed a significant decrease postoperatively (Table 2).
Elevations of serum markers above cutoff value were found
in 12 of 49 (25%) patients for CK, 3 of 49 (6%) patients for
CK-MB, 37 of 49 (76%) patients for myoglobin, 18 of 49
(37%) patients for cTNT and 7 of 49 (14%) patients for
cTNI, respectively. Accordingly, a threefold rise of CK,
CK-MB, myoglobin, cTNT and cTNI from baseline to
peak values was seen in 10 of 12 (83.3%), 2 of 3 (66.7%), 23
of 37 (62.2%), 13 of 18 (72.2%) and 7 of 7 (100%) patients,
respectively. The cTNT concentrations above cutoff level
were found to be related to increased serum creatinine values
in our studied population. Eight of 18 patients with peak
cTNT $0.1 ng/ml showed impaired renal function, with
serum creatinine .1.3 mg/dl as compared to 4 of 31
patients with peak cTNT concentrations below 0.1 ng/ml
(p 5 0.04). Mean serum creatinine was 2.5 6 2.6 mg/dl in
Table 2. Comparison of Mean Baseline and Peak Values of All Serum Markers
Baseline
Values
Preoperatively*
Peak Values
Postoperatively* p-Value
Total CK activity (U/l) 20.0 6 22.3 89.7 6 161.9 , 0.0001
(4–126) (19–1124)
CK-MB activity (U/l) 2.4 6 1.6 5.1 6 2.4 , 0.0001
(0–8) (1–12)
CK-MB/total CK (%) 19.0 6 16.7 9.9 6 7.4 0.0002
Myoglobin (mg/l) 74.1 6 228.2 261.0 6 779.3 , 0.0001
(25–1584) (38–5517)
Cardiac troponin T (ng/ml) 0.05 6 0.13 0.26 6 0.93 , 0.0001
(0.02–0.87) (0.02–6.46)
Cardiac troponin I (ng/ml) 0.3 6 0.1 0.8 6 1.0 , 0.0001
(0.3–0.7) (0.3–5.5)
*Mean 6 SD (range).
CK 5 creatine kinase.
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patients with cTNT $0.1 ng/ml as compared to 1.1 6
0.3 mg/dl in patients with cTNT ,0.1 ng/ml (p 5 0.007).
However, cTNI concentrations were unrelated to serum
creatinine values (Table 3).
In patients who received screw-in leads (16 of 49), CK
rose from 29.4 6 34.3 to 144.7 6 274.8 U/l (p 5 0.0004),
CK-MB from 2.2 6 1.3 to 5.5 6 3.3 U/l (p 5 0.001),
myoglobin from 141.0 6 385.9 to 513.2 6 1350.2 mg/l
(p 5 0.0004), cTNT from 0.11 6 0.22 to 0.6 6 1.6 ng/ml
(p 5 0.002), and cTNI from 0.33 6 0.1 to 0.8 6 1.3 ng/ml
(p 5 0.02). In patients with tined leads (33 of 49), CK rose
from 15.4 6 11.2 to 63.0 6 40.9 U/l (p , 0.0001), CK-MB
from 2.5 6 1.8 to 5.0 6 1.8 U/l (p , 0.0001), myoglobin
from 39.5 6 42.2 to 138.4 6 95.4 mg/l (p , 0.0001), cTNT
from 0.03 6 0.03 to 0.1 6 0.15 ng/ml (p , 0.0001), and
cTNI from 0.33 6 0.1 to 0.7 6 0.7 ng/ml (p 5 0.0007),
respectively. Comparison of mean baseline and peak values
of patients with tined versus screw-in leads revealed no
significant differences between both groups except for base-
line CK and cTNT values. Peak values, however, did not
differ significantly in patients with screw-in and patients
with tined lead systems.
Figure 1. Time course of changes in cardiac troponin I (cTNI) levels for each of the 49 study patients after ICD implantation. Preoperative
values are indicated by the first symbol in each curve at 0 h. The dotted line denotes the upper reference limit (cutoff) of the cTNI assay
used, which is 1.5 ng/ml. The bulky lines represent patients with cTNI concentrations above cutoff value, whereas patients with cTNI
concentrations below cutoff value are denoted by the thin lines.
Table 3. Characteristics of the 49 Studied Patients According to Levels of Cardiac Troponin I
Parameters
All Patients*
(n 5 49)
cTNI > 1.5 ng/ml*
(n 5 7)
cTNI < 1.5 ng/ml*
(n 5 42) p-Value
Cardiovascular disease
CAD 37/49 7/7 30/42 NS
Prior MI 30/49 7/7 23/42 0.03
MI within the last 6 months 6/49 3/7 3/42 0.03
LV ejection fraction (%) 33.8 6 16.4 28.9 6 12.9 34.6 6 16.9 NS
LV mass (g) 319.7 6 117.6 335.3 6 59.2 316.1 6 128.0 NS
LVEDD (mm) 63.2 6 9.1 62.7 6 7.7 63.3 6 9.4 NS
Serum creatinine (mg/dl) 1.6 6 1.7 1.3 6 0.3 1.7 6 1.8 NS
Additional leads 4/49 3/7 1/42 0.007
Active lead fixation 16/49 2/7 14/42 NS
Number of lead positions 1.7 6 1.0 2.9 6 1.3 1.5 6 0.9 0.009
Cumulative DFE (J) 111.2 6 62.7 203.0 6 107.7 95.9 6 35.1 0.01
Mean DFE (J) 15.4 6 4.1 20.0 6 4.8 14.6 6 3.4 0.005
Peak DFE (J) 30.8 6 6.2 33.6 6 1.6 30.4 6 6.6 NS
Cumulative VF time (s) 61.6 6 28.1 94.1 6 47.6 56.1 6 19.9 0.01
Number of VF inductions 4.8 6 1.5 6.1 6 2.3 4.6 6 1.2 NS
Number of shocks 7.0 6 2.5 10.4 6 4.5 6.5 6 1.5 0.04
Operation time (min) 94.9 6 41.5 149.3 6 70.4 85.8 6 26.5 0.008
*Data are presented as mean 6 SD or number of patients.
CAD 5 coronary artery disease; DFE 5 defibrillation energy; EDD 5 end diastolic diameter; LV 5 left ventricular; MI 5 myocardial infarction; NS 5 not significant; VF 5
ventricular fibrillation.
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Evaluation of cTNI concentrations. The time course of
changes in cTNI levels for each patient after ICD implan-
tation is shown in Figure 1. As illustrated, cTNI concen-
trations showed peak values in 2 of 7 patients 2 h, in 3 of 7
patients 8 h, and in 2 of 7 patients 24 h after ICD
implantation ranging from 1.7 ng/ml to 5.5 ng/ml. In 3 of
7 patients, the use of additional leads was required to fulfill
implantation criteria resulting in expanded DFT testing and
an increased number of shocks applied. In 1 of 7 patients,
dislocation of the ventricular lead occurred intraoperatively
after a shock discharge, thus requiring repositioning of the
lead and further DFT testing. Clinical parameters of pa-
tients with cTNI concentrations $1.5 ng/ml are listed in
Table 3. Univariate analysis showed cumulative DFE, mean
DFE, cumulative fibrillation time, number of shocks, prior
MI and recent MI within the last six months, use of an
additional lead system, number of lead positions as well as
operation time to be significantly related to cTNI concen-
trations elevated above cutoff level. A comparison of mean
DFE of patients with and without cTNI rise is shown in
Figure 2. No relationship to cTNI rise was found as to peak
DFE, lead fixation technique, the number of VF inductions,
LVEF, left ventricular mass or underlying heart disease
(Table 3). Multivariate analysis was performed to identify
independent risk factors for cTNI rise (Table 4). Mean
DFE $18 J proved to be predictive of a rise in cTNI
concentrations. The cTNI rise tended to be more frequent
in patients with a history of acute MI within the last six
months before ICD implantation. According to the odds
ratio given in Table 4, the risk of cTNI rise is considered
approximately 33-fold in patients with a mean DFE $18 J
and 10-fold in patients with a recent MI. Cumulative DFE,
cumulative fibrillation time, number of shocks per patient as
well as LVEF #30% were not predictive of cTNI rise.
Evaluation of follow-up data. In the perioperative period,
1 of 7 patients (14.3%) with cTNI levels above cutoff value
and 7 of 42 patients (16.7%) with cTNI concentrations
below 1.5 ng/ml experienced appropriate shock discharges
(p 5 1.0). During follow-up, 1 of 7 patients (14.3%) with
cTNI and 15 of 42 patients (35.7%) without cTNI rise
received appropriate shocks within the first six months after
ICD implantation (p 5 0.4). The mean number of shock
discharges per patient was 1.1 6 3 in patients with elevated
cTNI levels as compared to 2.9 6 6 in patients with cTNI
levels below cutoff (p 5 0.38). None of the seven patients
with elevated cTNI concentrations died during follow-up as
compared to 5 of 42 patients without cTNI rise (p 5 0.6).
DISCUSSION
During implantation of ICDs, both induction and termi-
nation of several episodes of VF are required to test the
correct function of the device. It has been reported from
intraoperative transesophageal echocardiographic studies
that ventricular function can be temporarily compromised
during ICD testing (1–3). However, there is less informa-
tion available about the degree and quantity of permanent
myocardial cell injury caused by ICD testing. Because
transvenous implantation procedures are less traumatic than
thoracotomy approaches using epicardial patch electrodes,
elevation of cardiac cell markers may not result from direct
mechanical trauma but is rather due to intraoperative
endocardial ICD testing. Hence, this prospective study was
Figure 2. Comparison of mean defibrillation energy applied dur-
ing ICD testing in patients with and without cTNI concentrations
elevated above cutoff value (1.5 ng/ml). cTNI 5 cardiac troponin
I; DFE 5 defibrillation energy.
Table 4. Analysis of Risk Factors for cTNI Rise Above Cutoff Level (Multivariate Analysis)
Odds Ratio
95% Confidence
Interval p-Value
MI within the last 6 months 9.83 0.31–309.99 NS
LVEF #30% 3.49 0.14–88.08 NS
Additional leads 0.17 0.00–4049.99 NS
Number of lead positions 2.8 0.42–18.52 NS
Cumulative DFE 1.0 0.99–1.02 NS
Mean DFE $18 J 33.2 1.05–1049.75 0.047
Cumulative VF time 1.0 0.9–1.12 NS
Number of shocks 1.15 0.31–4.25 NS
Operation time 1.02 0.96–1.07 NS
DFE 5 defibrillation energy; J 5 joule; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; NS 5 not
significant; VF 5 ventricular fibrillation.
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undertaken to assess the extent of myocardial cell injury in
patients undergoing DFT testing during transvenous ICD
implantation using conventional and new serum markers of
myocardial necrosis.
Assessment of all serum markers. A significant rise of
serum markers was found in all 49 patients postoperatively
with elevations of CK, CK-MB, myoglobin, cTNT and
cTNI above cutoff level in 25%, 6%, 76%, 37% and 14% of
the patients, respectively. Unlike CK and CK-MB, cTNT
and cTNI have been demonstrated to be sensitive and
highly specific markers for cardiac cell injury (11–18).
However, recent studies reported increased cTNT but
normal cTNI concentrations in patients with chronic renal
failure and skeletal muscle disease without evidence of
myocardial injury (28–30,37,38). Moreover, cTNT concen-
trations above cutoff level were also found to be significantly
related to increased serum creatinine concentrations in our
study population. Thus, cTNI was considered the most
sensitive and cardio-specific marker to assess myocardial cell
damage.
Assessment of cTNI. Increase of cTNI concentrations
above cutoff level was seen in 7 of 49 patients (14%) after
ICD implantation, with peak values ranging from 1.7 to
5.5 ng/ml indicating the presence of myocardial necrosis.
Unlike patients with transmural or non-Q-wave MI, cTNI
concentrations were only minimally elevated in our study
group. Because the amount of cTNI concentrations is
known to be related proportionally to the degree of myo-
cardial cell injury (11,23), peak cTNI concentrations mea-
sured in our patient group reflect only subtle myocardial
injury. These minor cTNI elevations should not be inter-
preted as possible ischemic or mechanical cardiac injury.
The fact that cTNI elevations were unrelated to the type of
underlying heart disease and technique used for lead fixation
suggests that cTNI elevations are probably due to defibril-
lation or fibrillation-related cardiac injury. Moreover, tined
leads were used in most of the patients that are known to be
less traumatic than screw-in leads.
The fact that minor degrees of myocardial cell injury can
be induced by electrical shocks is not unexpected and has
been demonstrated previously in patients after high-energy
transthoracic cardioversion (39–41). Recently, Allan et al.
(39) reported on 3 of 38 patients (7.9%) with elevated cTNI
concentrations ranging in value from 0.8 to 1.5 ng/ml after
direct current transthoracic shocks for elective cardioversion
of predominantly atrial fibrillation. The incidence of cTNI
rise in our patient population after conversion of several
episodes of VF was 14%, with peak values ranging from 1.7
to 5.5 ng/ml. The difference may be explained by the higher
number of shocks delivered in our patient population (7.0 6
2.5 vs. 2.1 6 1.2 shocks per patient) and the different
modalities shock energy was delivered (endocardial vs.
transthoracic application). In addition, blood samples were
started to be drawn 8 h after cardioversion in the study of
Allan and co-workers (39). Because cTNI may peak earlier,
as it has been shown in two patients of our study group,
some patients with elevated cTNI levels might have been
missed in the other study group.
Analysis of risk factors for cTNI rise. In addition to the
overall quantification of myocardial cell damage, we also
analyzed risk factors in patients prone to myocardial cell
injury due to ICD testing. In 4 of 7 patients with a rise of
cTNI, the implantation procedure was “complicated” either
by dislocation of the right ventricular electrode, requiring
repositioning, or by initial DFTs not fulfilling implantation
criteria, thus requiring implantation of additional lead
systems. As a consequence, intraoperative DFT testing was
expanded in those patients resulting in a higher number of
shocks, a higher cumulative DFE, and a longer fibrillation
time. It is noteworthy that there was no significant differ-
ence in number of VF inductions between patients with and
without cTNI rise. Despite testing of reversed polarity in
most patients, the mean number of VF inductions did not
exceed 4.8 attempts.
Univariate analysis revealed cumulative DFE, mean
DFE, cumulative fibrillation time, number of shocks and
prior MI indicative for myocardial cell injury. Mean DFE
$18 J and a recent MI within the last six months before
ICD implantation were found to be strong risk factors of
cTNI rise, with an odds ratio of 33 and 10, respectively. As
elevations of cTNI may persist up to 10 days after acute MI,
we did not include patients with ischemic events within 10
days before ICD implantation.
In contrast with our findings, no relation of cTNI rise to
the number of shocks, cumulative or peak energies was
found by Allan et al. (39) in patients after transthoracic
cardioversion for atrial fibrillation. This may be due to the
low number of patients with cTNI rise after cardioversion.
Among many variables it has been demonstrated that the
magnitude of myocardial cell damage is also dependent on
the time between successive shocks (42). Therefore, special
care was taken not to fall short of a minimum of 4 to 5 min
between successive arrhythmia inductions in our study.
Assessment of follow-up data. In patients with acute
coronary syndromes, cTNI concentrations proved to be of
prognostic importance (11,23). In our patient population,
however, elevated cTNI concentrations were found not to
be related to prognostic parameters such as mortality or
shock discharge rate, reflecting the minor degree of myo-
cardial cell injury caused during ICD testing.
Clinical implications. During transvenous implantation of
ICDs, myocardial cell damage as assessed by rise of cTNI
occurs in approximately 14% of patients. Because cumula-
tive and mean DFE, the number of shocks applied and the
cumulative fibrillation time are significantly related to myo-
cardial cell damage, intraoperative DFT testing should be
limited to a minimum number of arrhythmia inductions and
shocks delivered. Excessive test protocols for scientific
purposes should be reconsidered in the light of our results.
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Rapid and effective test protocols are preferable—for exam-
ple, binary-search algorithms. Patients with a recent MI
seem to be prone to cTNI rise, although revascularization
procedures were performed in each patient prior to ICD
implantation. This information is important because pro-
phylactic ICD implantation will become frequent in
post-MI patients in the near future.
Reprint requests and correspondence: Dr. Tanja M. Hurst,
Department of Cardiology, University of Giessen, Klinikstrasse
36, 35385 Giessen, Germany.
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